Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease

Abstract

Background & Aims p53 and its transcriptional target miRNA34a have been implicated in the pathogenesis of fatty liver. We tested the efficacy of a p53 inhibitor, pifithrin-α p-nitro (PFT) in attenuating steatosis, associated oxidative stress and apoptosis in a murine model of non-alcoholic fatty liver disease (NAFLD). Methods C75Bl/6J mice were fed a high-fat (HFD) or control diet for 8 weeks, PFT or DMSO (vehicle) were administered three times per week. Markers of oxidative stress and apoptosis as well as mediators of hepatic fatty acid metabolism were assessed by immunohistochemistry, Western-blot, real-time PCR and biochemical assays. Results PFT administration suppressed HFD-induced weight gain, ALT elevation, steatosis, oxidative stress and apoptosis. PFT treatment blunted the HFD-induced upregulation of miRNA34a and increased SIRT1 expression. In the livers of HFD-fed, PFT-treated mice activation of the SIRT1/PGC1α/PPARα axis increased the expression of malonyl-CoA decarboxylase (MLYCD), an enzyme responsible for malonyl-CoA (mCoA) degradation. Additionally, the SIRT1/LKB1/AMPK pathway (upstream activator of MLYCD) was promoted by PFT. Thus, induction of these two pathways by PFT diminished the hepatic mCoA content by enhancing MLYCD expression and function. Since mCoA inhibits carnitine palmitoyltransferase 1 (CPT1), the decrease of hepatic mCoA in the PFT-treated, HFD-fed mice increased CPT1 activity, favored fatty acid oxidation and decreased steatosis. Additionally, we also demonstrated that PFT abrogated steatosis and promoted MLYCD expression in palmitoleic acid- treated human HepaRG cells. Conclusions The p53 inhibitor PFT diminished hepatic triglyceride accumulation and lipotoxicity in mice fed a HFD by depleting mCoA and favoring the β-oxidation of fatty acids.